Cellular zinc status regulates cytomegalovirus major immediate-early promoter

Antiviral Research

Volumn 47, Issue 3, 2000, Pages 207-214

  Kanekiyo, Masako ^a   Itoh, Norio ^a   Mano, Mikiko ^a   Kawasaki, Atsuko ^a   Tanaka, Junji ^b   Muto, Norio ^a   Tanaka, Keiichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Fac Med Kanazawa U   (Japan)

Author keywords

Anti virus; CMV promoter; DTPA; Metallothionein; Zinc

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; PENTETIC ACID; ZINC;

ARTICLE; BONE MARROW TOXICITY; CELL STRAIN L 929; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; HUMAN; IMMEDIATE EARLY GENE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIGENS, VIRAL; CATIONS; CELLS, CULTURED; CHELATING AGENTS; CYTOMEGALOVIRUS; EMBRYO; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HUMANS; IMMEDIATE-EARLY PROTEINS; LUCIFERASES; METALLOTHIONEIN; PENTETIC ACID; PROMOTER REGIONS (GENETICS); ZINC;

EID: 0033819237     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00108-X     Document Type: Article

References (46)

1. Abdel-Mageed A.B., Agrawal K.C. Activation of nuclear factor κB: potential role in metallothionein-mediated mitogenic response. Cancer Res. 58:1998;2335-2338.
2. Aisen P., Listowsky I. Iron transport and storage proteins. Annu. Rev. Biochem. 49:1980;357-393.
3. Baskar J.F., Smith P.P., Ciment G.S., Hoffmann S., Tucker C., Tenney D.J., Colberg-Poley A.M., Nelson J.A., Ghazal P. Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J. Virol. 70:1996;3215-3226.
4. Bettger W.J., O'Dell B.L. A critical physiological role of zinc in the structure and function of biomembranes. Life Sci. 28:1981;1425-1438.
5. Boom R., Sol C.J., Minnaar R.P., Geelen J.L., Raap A.K., van-der-Noordaa J. Induction of gene expression under human cytomegalovirus immediate early enhancer-promoter control by inhibition of protein synthesis is cell cycle-dependent. J. Gen. Virol. 69:1988;1179-1193.
6. Bruening W., Giasson B., Mushynski W., Durham H.D. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res. 26:1998;486-489.
7. Chattopadhyay S., Freake H.C. Zinc chelation enhances thyroid hormone induction of growth hormone mRNA in GH3 cells. Mol. Cell. Endocrinol. 136:1998;151-157.
8. Chen C.A., Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques. 6:1988;632-638.
9. 2+ requirement for DNA synthesis by 3T3 cells. Exp. Cell Res. 184:1989;499-508.
10. Cinatl J. Jr, Cinatl J., Rabenau H., Gumbel H.O., Kornhuber B., Doerr H.W. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res. 25:1994;73-77.
11. Cinatl J. Jr, Hoffmann F., Cinatl J., Weber B., Scholz M., Rabenau H., Stieneker F., Kabickova H., Blasko M., Doerr H.W. In vitro inhibition of human cytomegalovirus replication by calcium trinatrium diethylenetriaminepentaacetic acid. Antiviral Res. 31:1996;23-34.
12. Coleman T.A., Chomczynski P., Frohman L.A., Kopchick J.J. A comparison of transcriptional regulatory element activities in transformed and non-transformed rat anterior pituitary cells. Mol. Cell. Endocrinol. 75:1991;91-100.
13. Eaton D.L., Toal B.F. Evaluation of the Cd/hemoglobin affinity assay for the rapid determination of metallothionein in biological tissues. Toxicol. Appl. Pharmacol. 66:1982;134-142.
14. Erice A., Jordan M.C., Chace B.A., Fletcher C., Chinnock B.J., Balfour H. Jr Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J. Am. Med. Assoc. 257:1987;3082-3087.
15. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3:1993;85-96.
16. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh. K. Acad. Geneesk. Belg. 58:1996;19-49.
17. Faia K.L., Rowe D.J., Bobilya D.J. Zinc status and cytokine effects on metallothionein (MT) content in bovine pulmonary arterial endothelial cells (BPAEC). FASEB J. 10:1996;530.
18. Felsenstein D., D'Amico D.J., Hirsch M.S., Neumeyer D.A., Cederberg D.M., de-Miranda P., Schooley R.T. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann. Intern. Med. 103:1985;377-380.
19. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status (see comments). New Engl. J. Med. 326:1992;663-667.
20. Gallant J.E., Moore R.D., Richman D.D., Keruly J., Chaisson R.E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group (see comments). J. Infect. Dis. 166:1992;1223-1227.
21. Grummt F., Weinmann-Dorsch C., Schneider-Schaulies J., Lux A. Zinc as a second messenger of mitogenic induction. Effects on diadenosine tetraphosphate (Ap4A) and DNA synthesis. Exp. Cell Res. 163:1986;191-200.
22. Gunes C., Heuchel R., Georgiev O., Muller K.H., Lichtlen P., Bluthmann H., Marino S., Aguzzi A., Schaffner W. Embryonic lethality and liver degeneration in mice lacking the metal-responsive transcriptional activator MTF-1. EMBO J. 17:1998;2846-2854.
23. Hecht D.W., Snydman D.R., Crumpacker C.S., Werner B.G., Heinze-Lacey B. Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia. J. Infect. Dis. 157:1988;187-190.
24. Heuchel R., Radtke F., Georgiev O., Stark G., Aguet M., Schaffner W. The transcription factor MTF-1 is essential for basal and heavy metal-induced metallothionein gene expression. EMBO J. 13:1994;2870-2875.
25. Kloover J.S., Scholz M., Cinatl J. Jr, Lautenschlager I., Grauls G.E., Bruggeman C.A. Effect of desferrioxamine(DFO) and calcium trinatrium diethylenetriaminepenteecetic acid(DTPA) on rat cytomegalovirus replication in vitro and in vivo. Antiviral Res. 44:1999;55-65.
26. Laskin O.L., Stahl-Bayliss C.M., Kalman C.M., Rosecan L.R. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J. Infect. Dis. 155:1987;323-327.
27. Lefebvre D., Beckers F., Ketelslegers J.M., Thissen J.P. Zinc regulation of insulin-like growth factor-I (IGF-I), growth hormone receptor (GHR) and binding protein (GHBP) gene expression in rat cultured hepatocytes. Mol. Cell. Endocrinol. 138:1998;127-136.
28. Maret W., Larsen K.S., Vallee B.L. Coordination dynamics of biological zinc 'clusters' in metallothioneins and in the DNA-binding domain of the transcription factor Gal4. Proc. Natl. Acad. Sci. USA. 94:1997;2233-2237.
29. Meier J.L., Stinski M.F. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology. 39:1996;331-342.
30. Meyers J.D., Flournoy N., Thomas E.D. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev. Infect. Dis. 4:1982;1119-1132.
31. Meyers J.D. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant. 3:1988;95-104.
32. 2+ availability affects the antizyme-dependent ornithine decarboxylase degradation pathway in isolated primary cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 243:1998;797-800.
33. Petrie L., Chesters J.K., Franklin M. Inhibition of myoblast differentiation by lack of zinc. Biochem. J. 276:1991;109-111.
34. Rubin R.H. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12:1990;S754-S766.
35. Saiki R.K., Gelfand D.H., Stoffel S., Scharf S.J., Higuchi R., Horn G.T., Mullis K.B., Erlich H.A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 239:1988;487-491.
36. Sambucetti L.C., Cherrington J.M., Wilkinson G.W., Mocarski E.S. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivation and by T cell stimulation. EMBO J. 8:1989;4251-4258.
37. Schmidt E.V., Christoph G., Zeller R., Leder P. The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol. Cell. Biol. 10:1990;4406-4411.
38. Scholz M., Blaheta R.A., Markus B.H., Doerr H.W., Cinatl J. Immunomodulation and anticytomegalovirus activity of antioxidant metal chelators. Transplant. Proc. 29:1997;1272-1273.
39. Searle P.F. Zinc dependent binding of a liver nuclear factor to metal response element MRE-a of the mouse metallothionein-I gene and variant sequences. Nucleic Acids Res. 18:1990;4683-4690.
40. Singer D.R., Fallon T.J., Schulenburg W.E., Williams G., Cohen J. Foscarnet for cytomegalovirus retinitis (letter). Ann. Intern. Med. 103:1985;962.
41. Stamminger T., Fickenscher H., Fleckenstein B. Cell type-specific induction of the major immediate early enhancer of human cytomegalovirus by cyclic AMP. J. Gen. Virol. 71:1990;105-113.
42. Tate D.J., Miceli M.V., Newsome D.A., Alcock N.W., Oliver P.D. Influence of zinc on selected cellular functions of cultured human retinal pigment epithelium. Curr. Eye Res. 14:1995;897-903.
43. Vallee B.L. The function of metallothionein. Neurochem. Int. 27:1995;23-33.
44. Walmsley S.L., Chew E., Read S.E., Vellend H., Salit I., Rachlis A., Fanning M.M. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J. Infect. Dis. 157:1988;569-572.
45. Wathen M.W., Stinski M.F. Temporal patterns of human cytomegalovirus transcription: mapping the viral RNAs synthesized at immediate early, early, and late times after infection. J. Virol. 41:1982;462-477.
46. Zeng J., Heuchel R., Schaffner W., Kagi J.H. Thionein (apometallothionein) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett. 279:1991;310-312.